Abeona Therapeutics Inc
F:PCJP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abeona Therapeutics Inc
F:PCJP
|
US |
|
C
|
China Shenhua Energy Co Ltd
XHAM:IKF
|
CN |
|
1st Source Corp
NASDAQ:SRCE
|
US |
|
Liberty Global PLC
NASDAQ:LBTYA
|
UK |
|
D
|
Deutsche Post AG
SWB:DHL
|
DE |
|
R
|
Renault SA
DUS:RNL
|
FR |
|
N
|
Novartis AG
BMV:NVSN
|
CH |
|
B
|
Bankinter SA
XBER:BAKA
|
ES |
|
Autodesk Inc
NASDAQ:ADSK
|
US |
|
H
|
Home Depot Inc
LSE:0R1G
|
US |
|
Realty Income Corp
BMV:O
|
US |
Abeona Therapeutics Inc
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare genetic diseases. It tries to fix the underlying DNA problem behind a disorder, rather than just treating symptoms. Its work has centered on diseases that affect the eyes, the immune system, and other inherited conditions with very limited treatment options. The company develops these therapies in-house and works through the long drug-development path of testing, seeking approval, and then bringing a treatment to market. Its customers are not everyday consumers; they are specialist doctors, hospitals, treatment centers, and the insurers or government programs that pay for rare-disease medicines. Abeona can make money through product sales if a therapy reaches the market, and it may also use licensing or collaboration deals tied to its drug candidates. What makes Abeona different is its role at the very high-risk, highly specialized end of the healthcare value chain. Instead of selling broad-usage medicines, it focuses on one-time or limited-use treatments for small patient groups where the scientific challenge is hard but the medical need is large. That makes the business much more dependent on clinical results, regulatory approval, and access to rare-disease treatment centers than a normal drug company.
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare genetic diseases. It tries to fix the underlying DNA problem behind a disorder, rather than just treating symptoms. Its work has centered on diseases that affect the eyes, the immune system, and other inherited conditions with very limited treatment options.
The company develops these therapies in-house and works through the long drug-development path of testing, seeking approval, and then bringing a treatment to market. Its customers are not everyday consumers; they are specialist doctors, hospitals, treatment centers, and the insurers or government programs that pay for rare-disease medicines. Abeona can make money through product sales if a therapy reaches the market, and it may also use licensing or collaboration deals tied to its drug candidates.
What makes Abeona different is its role at the very high-risk, highly specialized end of the healthcare value chain. Instead of selling broad-usage medicines, it focuses on one-time or limited-use treatments for small patient groups where the scientific challenge is hard but the medical need is large. That makes the business much more dependent on clinical results, regulatory approval, and access to rare-disease treatment centers than a normal drug company.
ZEVASKYN launch: Abeona said commercial momentum is building, with 5 patients treated to date, 6 qualified treatment centers active, and 95% of commercially covered lives now having published policies.
Quarterly revenue: First-quarter product revenue was $8.7 million, up from $2.4 million in Q4 2025, driven by early commercial traction and three commercial patients treated in the quarter.
Pipeline pivot: The company deprioritized its in-house ophthalmology preclinical programs and in-licensed PSMA-SIR-T, a prostate cancer cell therapy, with a pre-IND meeting planned for June 3, 2026 and first-in-human studies expected in the second half of 2027.
Launch outlook: Management said it remains on track to reach 7 QTCs this year, with internal capacity being built toward 10 sites by year-end and a longer-term goal of more centers if they have the right multidisciplinary teams.
Profitability view: CFO Joe Vazzano reiterated the company still believes it can potentially reach monthly profitability starting in June, depending on how biopsy volume develops.
